MedTrace Logo

Genetic Determinants of Response to Beta Blockade

NCT00837902 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2018-11-30

Study results available
· View outcomes & findings →

Summary

The overall goal of this project is to determine the genetic factors contributing to interindividual differences in response to beta-blockade.

Conditions

  • Healthy

Interventions

DRUG

Atenolol (β-blocker)

25 mg tablet

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Charles M Stein, MD · Vanderbilt University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00837902 on ClinicalTrials.gov